SCIEX Announces New BioPharmaView Software 3.0 for Streamlining Multiple-Attribute Methods (MAM)
The growing popularity of protein-based drugs as treatments for various illnesses has resulted in the need for new analytical methods that are faster and more cost-effective. The complex nature of biologics means that high-resolution, sensitive instruments are needed to identify differences between protein structures. The MAM Workflow has been specifically designed for use by biopharma researchers, with emphasis placed on making the technology easy to implement, learn and use. Biologics can now be characterized within shorter timescales and to a higher level of detail, including product quality attribute (PQA) monitoring, quantitation, and impurity monitoring. The burden of analyzing these data and reporting final results has also been simplified by integrating all necessary steps in the BioPharmaView software.
The SCIEX Workflow for MAM combines the high performance of a state-of-the-art mass spectrometer with the newly upgraded processing software. Currently, two SCIEX mass spectrometers are designed to integrate well with the MAM Workflow. Firstly, the SCIEX X500B QTOF System, which provides robust and simple therapeutic analyses in a single, compact and easy-to-use platform.
Alternatively, the high-performance SCIEX TripleTOF® 6600 System can be integrated into the workflow. This powerful system’s flexibility makes it capable of performing comprehensive characterization and quantitation while also allowing for MAM method development suitable for a biopharma laboratory.
BioPharmaView Software 3.0 comes complete with new features for performing a complete MAM workflow in a single software suite, along with the ability to automate core biologics characterization workflows, such as intact mass, subunit mass, and peptide mapping analyses. The BioPharmaView Software 3.0 has been built based on customer feedback, simplifying and automating the intensive data processing steps to make biotherapeutic characterization data processing faster, easier and more productive in a simplified view.
“Developing a powerful MAM Workflow for biotherapeutic product monitoring can provide orthogonal data to other conventional analytical assays, while providing deeper information on the biologic,” said Susan Darling, Senior Director, BioPharma Business at SCIEX. “In the future this may drive a reduction in the number of tests needed during biologic research, which may therefore have the effect of reducing development costs and accelerate the timeline and ensuring product quality.”
The development of the SCIEX solution for MAM workflow demonstrates SCIEX’s continual commitment to the success of the biopharma field. By requiring fewer characterization methods to be performed in tandem, and instead performing them in one LC-MS run, SCIEX provides solutions to companies looking for alternative cost-savings.
To learn more about SCIEX Solution for MAM please click here: sciex.com/MAM
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company’s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.
For Research Use Only. Not for use in diagnostic procedures. RUO-MKT-12-7724A
AB Sciex is operating as SCIEX.
©2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.